ASCO 2025, Non–muscle-Invasive Bladder Cancer (NMIBC), Intravesical Sacituzumab Tirumotecan, Intermediate-Risk Non–muscle-Invasive Bladder Cancer, TroFuse-027 Study, Trophoblast cell-surface antigen 2 ...

PSMA and Beyond 2025 CAR-T and Bispecific antibodies targeting PSMA, Poseida trial, neuroendocrine prostate cancer, STEAP-1.

AUA 2025, Metastatic Renal Cell Carcinoma (mRCC), Maximal Evaluable Lesion Size in Patients with Metastatic Renal Cell Carcinoma, Nivolumab plus Ipilimumab Combination Therapy, nivolumab, ipilimumab, ...

AUA 2025 Tokai Urologic Oncology Research Study (TOURS) database study, tyrosine kinase inhibitors (TKIs), immunotherapy (IO), advanced renal cell carcinoma (RCC).

PSMA and Beyond 2025 CA-IX in renal cell cancer (RCC), ZIRCON, kidney cancer, stage migration for RCC, REDECT trial, renal mass biopsy, girentuximab.

SNMMI 2025 utility of the PROSTest to predict response to 177Lu-PSMA therapy in metastatic castration resistant prostate cancer (mCRPC), blood-based 27-marker gene mRNA expression machine ...

pasritamig, KLK2 T-cell engager, bispecific antibody prostate cancer, Phase I trial results, mCRPC immunotherapy, Pasritamig Safety and Efficacy Data from Metastatic CRPC Phase I Study with Capucine ...

Andrea Miyahira hosts Marina Sharifi about a multiomic profiling study of metastatic castration-resistant prostate cancer using circulating tumor cells, ctDNA, and RNA sequencing.